Vol 1, No 1 (June 2012): Translational Cancer Research

Editorials

Translational Cancer Research - Message from the Editor-in-Chief

Eric Y Chuang, Sc.D.

PDF Pages: 1 Full Text Open Access

DNA-PK targeting virotherapy, a promising approach

Koji Tsuboi

PDF Pages: 2-3 Full Text Open Access

Inhibitors of DNA repair for cancer therapy, ready for prime time?

Chuan-Yuan Li

PDF Pages: 4-5 Full Text Open Access

Original Article

Oncolytic virus-mediated tumor radiosensitization in mice through DNA-PKcs-specific shRNA

Takashi Kon, Xiuwu Zhang, Qian Huang, Zhonghui Yang, Shanling Liu, Bin Yan, Fang Li, He Wang, Chuan-Yuan Li

PDF Pages: 6-14 Full Text Open Access

Review Articles

SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis

Seong-Hoon Park, Yuming Zhu, Ozkan Ozden, Hyun-Seok Kim, Haiyan Jiang, Chu-Xia Deng, David Gius, Athanassios Vassilopoulos

PDF Pages: 15-21 Full Text Open Access

Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment

Feng-Ming Hsu, Shichuan Zhang, Benjamin P.C. Chen

PDF Pages: 22-34 Full Text Open Access

Normal tissue protection for improving radiotherapy: where are the Gaps?

Pataje G.S. Prasanna, Helen B. Stone, Rosemary S. Wong, Jacek Capala, Eric J. Bernhard, Bhadrasain Vikram, C. N. Coleman

PDF Pages: 35-48 Full Text Open Access

Perspective

Anti-HER2 therapies: when more is more

Monica Arnedos, Britta Weigelt, Jorge S. Reis-Filho

PDF Pages: 49-54 Full Text Open Access

Research Highlights

Bevacizumab: where do we go from here in breast cancer?

Faina Nakhlis, Mehra Golshan

PDF Pages: 55-56 Full Text Open Access

Neoadjuvant bevacizumab and chemotherapy in breast cancer

Suparna B. Wedam, Sherry X. Yang

PDF Pages: 57-58 Full Text Open Access